Section Arrow
ONCT.NASDAQ
- Oncternal Therapeutics
Quotes are at least 15-min delayed:2024/12/24 12:50 EST
Last
 --
-- (--)
Day High 
-- 
Prev. Close
0.5266 
1-M High
0.84 
Volume 
-- 
Bid
--
Ask
--
Day Low
-- 
Open
-- 
1-M Low
0.5266 
Market Cap 
1.56M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.9 
20-SMA 1.12 
50-SMA 1.29 
52-W High 11.446 
52-W Low 0.5266 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-11.69/-8.12
Enterprise Value
1.70M
Balance Sheet
Book Value Per Share
3.09
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
1.20
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TNXPTonix Pharmaceuticals Holding Corp.0.384-0.0191-4.74%-- 
CMNDClearmind Medicine1.68+0.46+37.70%0.16PE
CEROCERo Therapeutics Holdings0.0603+0.0098+19.41%-- 
RXRXRecursion Pharmaceuticals7.3+0.31+4.43%-- 
CDTConduit Pharmaceuticals0.0576+0.0031+5.69%-- 
Quotes are at least 15-min delayed:2024/12/24 12:50 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.